Literature DB >> 7828973

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease.

N Banatvala1, G R Davies, Y Abdi, L Clements, D S Rampton, J M Hardie, R A Feldman.   

Abstract

A high prevalence of metronidazole resistance in Helicobacter pylori is reported in developing countries. This study examined whether migrants referred for diagnostic gastroscopy at a United Kingdom centre (n = 54), had a higher prevalence of metronidazole resistance than subjects born in the United Kingdom attending endoscopy (n = 46). Records of nitroimidazole treatment prescribed in the United Kingdom was obtained in 83 patients to find out if there was an association between H pylori metronidazole resistance and previous ingestion of either metronidazole or tinidazole. The prevalence of metronidazole resistant isolates varied according to country of birth: Bangladesh (90%, 27 of 30), other countries (67%, 16 of 24), and United Kingdom (37%, 17 of 46) (p < 0.001). Among those born in the United Kingdom, women were more likely to harbour resistant H pylori than men (54% v 18% respectively, p = 0.01) and more likely to have a history of previous nitroimidazole ingestion (41% v 11% respectively, p = 0.02). Patients previously exposed to either metronidazole or tinidazole were more likely to harbour resistant strains (84% (27 of 32) v 41% (21 or 51), p < 0.0001). The distribution of gastroduodenal disease, assessed endoscopically, was not affected by metronidazole resistance status.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7828973      PMCID: PMC1375612          DOI: 10.1136/gut.35.11.1562

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Metronidazole resistance in Helicobacter pylori.

Authors:  Y Glupczynski; A Burette; E De Koster; J F Nyst; M Deltenre; S Cadranel; L Bourdeaux; D De Vos
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

2.  Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals.

Authors:  D M Musher; R E Baughn; G B Templeton; J N Minuth
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

3.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains.

Authors:  G Ravizzola; F Pirali; A Paolucci; L Terlenghi; L Peroni; A Colombi; A Turano
Journal:  J Antimicrob Chemother       Date:  1987-12       Impact factor: 5.790

5.  Over the counter drugs in Bangladesh.

Authors:  M A Azhar; H A Ahasan; M A Chowdhury; A K Rafiqueuddin
Journal:  BMJ       Date:  1993-11-27

6.  Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo.

Authors:  C J Dorman; S Chatfield; C F Higgins; C Hayward; G Dougan
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  Comparison of enterotoxins and haemolysins produced by methicillin-resistant (MRSA) and sensitive (MSSA) Staphylococcus aureus.

Authors:  J E Coia; L Browning; L Haines; T H Birkbeck; D J Platt
Journal:  J Med Microbiol       Date:  1992-03       Impact factor: 2.472

8.  Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content.

Authors:  F Megraud; F Bonnet; M Garnier; H Lamouliatte
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

9.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

10.  Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  L E Bryan; K O'Hara; S Wong
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

View more
  22 in total

1.  In vitro activities of new quinolones against Helicobacter pylori.

Authors:  M Carbone; M T Fera; V Cecchetti; O Tabarrini; E Losi; V Cusumano; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

2.  Treating Helicobacter pylori--the best is yet to come?

Authors:  A Harris; J J Misiewicz
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.

Authors:  J J Misiewicz; A W Harris; K D Bardhan; S Levi; C O'Morain; B T Cooper; G D Kerr; M F Dixon; H Langworthy; D Piper
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

4.  Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori.

Authors:  J Tankovic; D Lamarque; J C Delchier; C J Soussy; A Labigne; P J Jenks
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.

Authors:  M Sörberg; H Hanberger; M Nilsson; A Björkman; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  One week treatment for Helicobacter pylori infection.

Authors:  D Walsh; N Goggin; M Rowland; M Durnin; S Moriarty; B Drumm
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

Review 7.  Drug targets and mechanisms of resistance in the anaerobic protozoa.

Authors:  P Upcroft; J A Upcroft
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

Review 8.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

9.  Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands.

Authors:  E J van der Wouden; A A van Zwet; G D Vosmaer; J A Oom; A de Jong; J H Kleibeuker
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

10.  Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Authors:  M J Buckley; H X Xia; D M Hyde; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.